Annals of Clinical and Translational Neurology

Article	Citations
Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”	421
Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patients	342
Blood neurofilament light: a critical review of its application to neurologic disease	131
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France	86
Anakinra usage in febrile infection related epilepsy syndrome: an international cohort	79
Long COVID‐19: Objectifying most self‐reported neurological symptoms	68
Repeat expansion scanning of the NOTCH2NLC gene in patients with multiple system atrophy	67
Longitudinal biomarkers in amyotrophic lateral sclerosis	64
De Novo Status Epilepticus in patients with COVID‐19	59
Serious safety events in rituximab‐treated multiple sclerosis and related disorders	59
Neurological manifestations of coronavirus infections – a systematic review	56
Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study	56
Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID‐19	53
Seizures and risk of epilepsy in anti‐NMDAR, anti‐LGI1, and anti‐GABABR encephalitis	52
Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study	52
Improved ALS clinical trials through frequent at‐home self‐assessment: a proof of concept study	51
Retraining and control therapy for pediatric psychogenic non‐epileptic seizures	50
Brain dysfunction in COVID‐19 and CAR‐T therapy: cytokine storm‐associated encephalopathy	50
Comparison of SimoaTM and EllaTM to assess serum neurofilament‐light chain in multiple sclerosis	47
230 days of ultra long‐term subcutaneous EEG: seizure cycle analysis and comparison to patient diary	47
Cortical hyperexcitability evolves with disease progression in ALS	46
Centromedian thalamic responsive neurostimulation for Lennox‐Gastaut epilepsy and autism	46
Evolution of neurologic symptoms in non‐hospitalized COVID‐19 “long haulers”	43
Diaphragm dysfunction in severe COVID‐19 as determined by neuromuscular ultrasound	43
Experiences of telemedicine in neurological out‐patient clinics during the COVID‐19 pandemic	43

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease	42
Role of homocysteine in the development and progression of Parkinson’s disease	41
The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults	40
Neuronal intranuclear inclusion disease is genetically heterogeneous	40
Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS	40
A rapid α‐synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy	39
Re‐defining the clinicopathological spectrum of neuronal intranuclear inclusion disease	39
Acute disseminated encephalomyelitis in a patient vaccinated against SARS‐CoV‐2	37
The brain–heart interaction in epilepsy: implications for diagnosis, therapy, and SUDEP prevention	37
Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study	37
Developmental regression and mitochondrial function in children with autism	37
Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder	37
QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions	37
Validation of differentially expressed brain‐enriched microRNAs in the plasma of PD patients	36
Spreading in ALS: The relative impact of upper and lower motor neuron involvement	35
Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis	34
Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients	34
Automated cot‐side tracking of functional brain age in preterm infants	33
Prolonged confusional state as first manifestation of COVID‐19	33
Spinocerebellar ataxia clinical trials: opportunities and challenges	33
Genetic modifiers of respiratory function in Duchenne muscular dystrophy	32
Cerebellar cognitive disorder parallels cerebellar motor symptoms in Friedreich ataxia	32
Interictal spike networks predict surgical outcome in patients with drug‐resistant focal epilepsy	32
The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes	32
Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy	31
Obesity and the risk of Multiple Sclerosis. The role of Leptin	31
Elevated matrix metalloproteinase‐9 levels in neuronal extracellular vesicles in Alzheimer’s disease	31
Deep learning with diffusion basis spectrum imaging for classification of multiple sclerosis lesions	31
Artificial intelligence extension of the OSCAR‐IB criteria	30
Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children	30
Early life metal dysregulation in amyotrophic lateral sclerosis	30
Walking in multiple sclerosis improves with tDCS: a randomized, double‐blind, sham‐controlled study	29
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment	29
Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease	28
Intrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome	28
Ring trial of 2nd generation RT‐QuIC diagnostic tests for sporadic CJD	27
CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis	27
Synaptic density in carriers of C9orf72 mutations: a [11C]UCB‐J PET study	27
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma	27
Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes	27
11C‐PK11195 PET–based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis	27
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy	27
Parkinson disease clinical subtypes: key features & clinical milestones	27
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy	27
LAMA2‐related muscular dystrophy: Natural history of a large pediatric cohort	26
Multiple sclerosis, rituximab, and COVID‐19	26
Adeno‐associated virus serotype 1‐based gene therapy for FTD caused by GRN mutations	26
Comparing progression biomarkers in clinical trials of early Alzheimer’s disease	26
Vocal music enhances memory and language recovery after stroke: pooled results from two RCTs	26
Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases	25

Clinical efficacy of plasma exchange in patients with autoimmune encephalitis	25
Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population	25
Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy	25
Neuronal RNA‐binding protein dysfunction in multiple sclerosis cortex	25
HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor	25
Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré Syndrome	25
Delta power robustly predicts cognitive function in Angelman syndrome	24
Longitudinal evaluation of neurologic‐post acute sequelae SARS‐CoV‐2 infection symptoms	24
Mendelian etiologies identified with whole exome sequencing in cerebral palsy	24
Prevalence and patterns of symptoms of dysautonomia in patients with long‐COVID syndrome: A cross‐sectional study	24
Gradient of brain mosaic RHEB variants causes a continuum of cortical dysplasia	24
Remote ischemic conditioning combined with intravenous thrombolysis for acute ischemic stroke	24
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients	24
Idebenone increases chance of stabilization/recovery of visual acuity in OPA1‐dominant optic atrophy	23
Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis	23
Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses	23
Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface	23
Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review	23
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease	23
Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia	23
Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?	23
Mortality of neuromyelitis optica spectrum disorders in a Chinese population	22
Long‐read whole‐genome sequencing for the genetic diagnosis of dystrophinopathies	22
Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy	22
Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study	22
White matter and neurite morphology differ in psychogenic nonepileptic seizures	22
Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder	22
Trait impulsivity in Juvenile Myoclonic Epilepsy	21
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment	21
Multiple sclerosis and inflammatory bowel disease: A systematic review and meta‐analysis	21
Transmission of CJD from nasal brushings but not spinal fluid or RT‐QuIC product	21
Impaired proteasome activity and neurodegeneration with brain iron accumulation in FBXO7 defect	21
Association of rare variants in neurodegenerative genes with familial Alzheimer’s disease	21
Gut microbiome is associated with multiple sclerosis activity in children	21
A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS	21
Brain volumetric deficits in MAPT mutation carriers: a multisite study	21
Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis	20
KCNQ2‐DEE: developmental or epileptic encephalopathy?	20
Development of an age‐adjusted model for blood neurofilament light chain	20
Genetic factors for susceptibility to and manifestations of neuromyelitis optica	20
Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis	20
Comparison of plasma and CSF biomarkers in predicting cognitive decline	20
A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica	20
Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases	20
Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy	20
Mechanistic underpinning of an inside–out concept for autoimmunity in multiple sclerosis	20
Impaired phonemic discrimination in logopenic variant primary progressive aphasia	20
Tau pathology associates with in vivo cortical thinning in Lewy body disorders	19
Leveraging electronic health records data to predict multiple sclerosis disease activity	19
Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease	19
Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy	19
Impaired cerebral autoregulation is associated with poststroke cognitive impairment	19
The influence of white matter hyperintensity on cognitive impairment in Parkinson's disease	19
CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis	19
Resection of piriform cortex predicts seizure freedom in temporal lobe epilepsy	19
Subcortical short‐term plasticity elicited by deep brain stimulation	19
Motor beta cortical oscillations are related with the gait kinematics of youth with cerebral palsy	19
Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease	19
Effect of diabetes control status on the progression of Parkinson’s disease: A prospective study	19
Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9	18
Clinical utility of anti‐cytosolic 5’‐nucleotidase 1A antibody in idiopathic inflammatory myopathies	18
Habitual sleep disturbances and migraine: a Mendelian randomization study	18
GGC repeat expansions in NOTCH2NLC causing a phenotype of distal motor neuropathy and myopathy	18
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy	18
Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD)	18
A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders	18
Vorinostat in the acute neuroinflammatory form of X‐linked adrenoleukodystrophy	18
Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers	18
TDP‐43 as structure‐based biomarker in amyotrophic lateral sclerosis	17
Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials	17
Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study	17
Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers	17
Demographic characteristics and neuropsychological assessments of subjective cognitive decline (SCD) (plus)	17
Relation of plasma β‐amyloid, clusterin, and tau with cerebral microbleeds: Framingham Heart Study	17
Younger age of stroke in low‐middle income countries is related to healthcare access and quality	17
SARS‐COV‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder	17
Acute epileptiform abnormalities are the primary predictors of post‐stroke epilepsy: a matched, case–control study	17
Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis	17
Prognostic value of serum/plasma neurofilament light chain for COVID‐19‐associated mortality	17
Reversing 21 years of chronic paralysis via non‐invasive spinal cord neuromodulation: a case study	17

Cognitive reserve and midlife vascular risk: Cognitive and clinical outcomes	17
GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease	16
Mutated RAP1GDS1 causes a new syndrome of dysmorphic feature, intellectual disability & speech delay	16
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis	16
Sustained immunotolerance in multiple sclerosis after stem cell transplant	16
Genetic prediction of impulse control disorders in Parkinson's disease	16
Consistent improvement with eculizumab across muscle groups in myasthenia gravis	16
MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous	16
Accuracy of FGF‐21 and GDF‐15 for the diagnosis of mitochondrial disorders: A meta‐analysis	16
Lipid levels and the risk of dementia: A dose–response meta‐analysis of prospective cohort studies	16
Effect of plasma exchange in neuromyelitis optica spectrum disorder: A systematic review and meta‐analysis	16
Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies	16
A meta‐analysis of the global impact of the COVID‐19 pandemic on stroke care & the Houston Experience	16
aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis	16
Whole‐exome and HLA sequencing in Febrile infection‐related epilepsy syndrome	15
Evolution of white matter damage in amyotrophic lateral sclerosis	15
Altered coupling between resting‐state glucose metabolism and functional activity in epilepsy	15
Machine learning prediction of the adverse outcome for nontraumatic subarachnoid hemorrhage patients	15
Baseline characteristics of the North American prodromal Synucleinopathy cohort	15
Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study	15
Safety and efficacy of unilateral and bilateral pallidotomy for primary dystonia	15
Neurodegeneration trajectory in pediatric and adult/late DM1: A follow‐up MRI study across a decade	15
Neuroprotective effects of FK866 against traumatic brain injury: Involvement of p38/ERK pathway	15
Central nervous system vascular malformations: A clinical review	15
Lack of progression of beta dynamics after long‐term subthalamic neurostimulation	15
Amyloid‐β PET and CSF in an autopsy‐confirmed cohort	15
Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis	15
Hippocampal sclerosis, TDP‐43, and the duration of the symptoms of dementia of AD patients	15
UCHL1 from serum and CSF is a candidate biomarker for amyotrophic lateral sclerosis	15
In‐depth peripheral CD4+ T profile correlates with myasthenic crisis	14
Sirolimus for epileptic seizures associated with focal cortical dysplasia type II	14
Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization	14
Association between amphetamine‐related disorders and dementia‐a nationwide cohort study in Taiwan	14
Heritability of alpha and sensorimotor network changes in temporal lobe epilepsy	14
Biallelic GRM7 variants cause epilepsy, microcephaly, and cerebral atrophy	14
Cognitive impairment in patients with Neuro‐Sjögren	14
Assessing the role of rare genetic variants in drug‐resistant, non‐lesional focal epilepsy	14
Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes	14
Early‐onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late‐onset	13
Evaluation of SORD mutations as a novel cause of Charcot‐Marie‐Tooth disease	13
Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer’s pathology	13
Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months	13
Effects of PB‐TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts	13
Factors influencing the acute pentylenetetrazole‐induced seizure paradigm and a literature review	13
Congenital myasthenic syndrome in China: genetic and myopathological characterization	13
Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration	13
Spinocerebellar ataxia type 14: refining clinicogenetic diagnosis in a rare adult‐onset disorder	13
CD8+ T cell subpopulations and pro‐inflammatory cytokines in neuromyelitis optica spectrum disorder	13
Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle	13
Ocular ultrasonography to detect intracranial pressure in aneurysmal subarachnoid hemorrhage	13
Predictors of cognitive decline in older individuals without dementia: An updated meta‐analysis	13
Optic, trigeminal, and facial neuropathy related to anti‐neurofascin 155 antibody	13
No strong HLA association with MOG antibody disease in the UK population	13
Structural brain changes in post‐acute COVID‐19 patients with persistent olfactory dysfunction	12
Functional dystonia: A case‐control study and risk prediction algorithm	12
Electrophysiological properties and seizure networks in hypothalamic hamartoma	12
Reliability and accuracy of EEG interpretation for estimating age in preterm infants	12
Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV	12
Novel SPTBN2 gene mutation and first intragenic deletion in early onset spinocerebellar ataxia type 5	12
Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome	12
Functional and pharmacological evaluation of a novel SCN2A variant linked to early‐onset epilepsy	12
Dopamine D1 + D3 receptor density may correlate with parkinson disease clinical features	12
Education, intelligence, and amyotrophic lateral sclerosis: A Mendelian randomization study	12
Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease	12
Physical activity level and stroke risk in US population: A matched case–control study of 102,578 individuals	12
Anakinra treatment for refractory cerebral autoinflammatory responses	12
Diagnostic capabilities of nanopore long‐read sequencing in muscular dystrophy	12
Recognizing early MRI signs (or their absence) is crucial in diagnosing metachromatic leukodystrophy	12
Systematic review of CMTX1 patients with episodic neurological dysfunction	12
Abolishing spontaneous epileptiform activity in human brain tissue through AMPA receptor inhibition	12
Characteristics and outcome of facial nerve palsy from Lyme neuroborreliosis in the United States	12
Home‐based biofeedback speech treatment improves dysarthria in repeat‐expansion SCAs	12
Initial findings in traumatic peripheral nerve injury and repair with diffusion tensor imaging	12
Test–retest reliability of the Friedreich’s ataxia rating scale	12
The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis	11
Excitatory and inhibitory neuron defects in a mouse model of Scn1b‐linked EIEE52	11
Genetic variation contributes to gene expression response in ischemic stroke: an eQTL study	11
Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review	11
Swallowing‐related neural oscillation: an intracranial EEG study	11
Peripheral synucleinopathy in Parkinson disease with LRRK2 G2385R variants	11
Using urine to diagnose large‐scale mtDNA deletions in adult patients	11
Plasma lipidomics of monozygotic twins discordant for multiple sclerosis	11
Longitudinal study on nerve ultrasound and corneal confocal microscopy in NF155 paranodopathy	11
Risk of incident autoimmune diseases in patients with thymectomy	11
Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort	11
National and subnational burden of stroke in Iran from 1990 to 2019	11
Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease	11
Digital endpoints for self‐administered home‐based functional assessment in pediatric Friedreich’s ataxia	11
Genetic spectrum in a cohort of patients with distal hereditary motor neuropathy	11
Expanding the clinical and genetic heterogeneity of SPAX5	11
Evaluation of peripherin in biofluids of patients with motor neuron diseases	11
Expanding the phenotypic spectrum of BCS1L‐related mitochondrial disease	11
Long‐term continuation of anti‐seizure medications after acute stroke	11
Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis	11
The CSF Levels of Neutrophil‐Related Chemokines in Patients with Neuromyelitis Optica	11